Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients

NCT04718480 is registered in ClinicalTrials.gov with SigmaDrugs Research Ltd. as lead sponsor.

NCT NCT04718480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients
Lead sponsor
SigmaDrugs Research Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2020
Completion date
May 31, 2022
Enrollment
66 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19